Novo Nordisk news - the latest biotech news from Labiotech.eu

Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity

Jim Cornall — Thu, 13 Apr 2023 10:00:00 +0000

Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […]

The post Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Debiopharm adds to oncology pipeline

Jim Cornall — Fri, 03 Mar 2023 09:53:56 +0000

Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in late preclinical development. FT-3171 (Debio 0432) could […]

The post Debiopharm adds to oncology pipeline appeared first on Labiotech.eu.

Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study

Jim Cornall — Fri, 10 Feb 2023 11:19:11 +0000

Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […]

The post Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study appeared first on Labiotech.eu.

Is Copenhagen the world capital of life science?

Jim Cornall — Tue, 17 Jan 2023 11:07:14 +0000

Denmark’s leading life science companies, public foundations, municipalities, universities and hospitals will work together to position Copenhagen as the world capital of life science through the newly-launched Copenhagen Life Science partnership. Tackling obesity is the first step in this public-private partnership. In 2022, the Danish government invested 82 million DKK ($11.7 million) to strengthen and […]

The post Is Copenhagen the world capital of life science? appeared first on Labiotech.eu.

FDA clears insulin pen medical device

Jim Cornall — Wed, 07 Dec 2022 12:39:21 +0000

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […]

The post FDA clears insulin pen medical device appeared first on Labiotech.eu.

Novo Nordisk announces $750M facility expansion

Jim Cornall — Wed, 23 Nov 2022 10:02:56 +0000

Novo Nordisk has announced plans to invest DKK 5.4 bn ($750m) in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global […]

The post Novo Nordisk announces $750M facility expansion appeared first on Labiotech.eu.

Novo Nordisk supports Plant2Food platform with €27M funding

Liza Laws — Thu, 10 Nov 2022 13:27:56 +0000

Novo Nordisk Foundation will support new open collaborative platform, Plant2Food, to accelerate the development of plant-based foods with up to €27 million ($26.9m) over the next five years. The platform, Plant2Food, will include researchers and companies collaborating and exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking […]

The post Novo Nordisk supports Plant2Food platform with €27M funding appeared first on Labiotech.eu.

ASPIRE set up to collaborate on amyloidosis

Jim Cornall — Tue, 04 Oct 2022 14:45:17 +0000

A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […]

The post ASPIRE set up to collaborate on amyloidosis appeared first on Labiotech.eu.

Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research

Jim Cornall — Wed, 21 Sep 2022 08:20:38 +0000

The Novo Nordisk Foundation has awarded a grant of $200 million to establish the first full-scale quantum computer for the development of new medicines. The computer will also provide new insights into climate change and the green transition, which is not possible with classical computers today. The computer could be located in a data center, […]

The post Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research appeared first on Labiotech.eu.

More companies enter BioInnovation Institute Venture Lab program

Jim Cornall — Tue, 06 Sep 2022 14:56:16 +0000

Nine ventures and two projects have become the latest addition to The BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BioInnovation Institute is an international commercial non-profit foundation based in Denmark, which incubates and accelerates life science research. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – […]

The post More companies enter BioInnovation Institute Venture Lab program appeared first on Labiotech.eu.

Report shows growth of life sciences sector in eastern Denmark

Jim Cornall — Mon, 06 Jun 2022 14:30:48 +0000

A new report on the Danish contribution to the Medicon Valley has been published. The report, Life Science in Eastern Denmark – The Danish Part of Medicon Valley is a survey of companies in the sector. Medicon Valley spans the Danish region of Zealand and the Capital Region, and the Skåne region of southern Sweden. […]

The post Report shows growth of life sciences sector in eastern Denmark appeared first on Labiotech.eu.

Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments

Dan Samorodnitsky — Mon, 17 Jan 2022 16:07:20 +0000

The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant Novo Nordisk to search for treatments controlling food intake and other factors contributing to obesity. Under the joint project, EraCal and Novo Nordisk will research targets for obesity treatments by identifying molecules that can control appetite and improve metabolic health. […]

The post Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments appeared first on Labiotech.eu.

The Future of Diabetes Treatment: Is a Cure Possible?

Clara Rodríguez Fernández — Mon, 15 Nov 2021 12:25:00 +0000

Diabetes has become an epidemic, sentencing over 460 million people worldwide to lifelong medication. Science is striving to find a diabetes treatment that can cure this chronic disease, but how close are we? Diabetes is the major cause of blindness, kidney failure, heart attack, and stroke. It is estimated that the number of people affected […]

The post The Future of Diabetes Treatment: Is a Cure Possible? appeared first on Labiotech.eu.

Novo Nordisk Foundation Pumps €85M into Carbon Capture Research

Anita Chakraverty — Fri, 01 Oct 2021 11:52:43 +0000

As pressure mounts to tackle climate change, the Danish Novo Nordisk Foundation has granted €84.7M to the world’s first research institution dedicated to capturing carbon dioxide from the air and harnessing the gas as a raw material. The new Novo Nordisk Foundation CO2 Research Center has the mission to efficiently capture, store, and recycle the […]

The post Novo Nordisk Foundation Pumps €85M into Carbon Capture Research appeared first on Labiotech.eu.

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Jonathan Smith — Tue, 08 Jun 2021 15:51:45 +0000

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

The post Farxiga’s Approval Fuels Chronic Kidney Disease Comeback appeared first on Labiotech.eu.

Novo Nordisk Foundation Commits €100M Grant to Developing Green Tech

Helen Albert — Mon, 15 Jun 2020 15:27:49 +0000

The Novo Nordisk Foundation has awarded a five-year grant of €100M to the DTU Biosustain research center near Copenhagen to support the development of sustainable green technology. DTU Biosustain was founded in 2011 and forms part of the Danish Technical University. The Novo Nordisk Foundation, which is one of the largest charitable foundations in the […]

The post Novo Nordisk Foundation Commits €100M Grant to Developing Green Tech appeared first on Labiotech.eu.

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Helen Albert — Wed, 13 May 2020 15:28:55 +0000

Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […]

The post Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon appeared first on Labiotech.eu.

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

Clara Rodríguez Fernández — Tue, 03 Mar 2020 14:00:20 +0000

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

The post How Immunotherapy Could Stop and Prevent Type 1 Diabetes appeared first on Labiotech.eu.

Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing

Jonathan Smith — Wed, 09 Oct 2019 16:13:34 +0000

The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company bluebird bio to develop next-generation gene editing treatments for hemophilia. The collaboration will last for three years and has the goal of developing a gene therapy that can permanently treat hemophilia A, a genetic disease causing uncontrolled bleeding. Novo Nordisk […]

The post Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing appeared first on Labiotech.eu.

FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug

Jonathan Smith — Mon, 23 Sep 2019 15:56:04 +0000

The first oral drug for type 2 diabetes belonging to the class of GLP-1 agonists, developed by Novo Nordisk, has got the go-ahead from the FDA. The Danish company is known for its blockbuster injectable drug in the same class — liraglutide — that is now one of the most highly prescribed drugs in the […]

The post FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug appeared first on Labiotech.eu.